Target Information
| Target General Infomation | |||||
|---|---|---|---|---|---|
| Target ID |
T92138
|
||||
| Former ID |
TTDC00315
|
||||
| Target Name |
Phosphodiesterase
|
||||
| Target Type |
Clinical Trial
|
||||
| Disease | Angina pectoris [ICD9: 413; ICD10: I20] | ||||
| Target Validation |
T92138
|
||||
| UniProt ID | |||||
| Sequence |
RPRGLGRIPELQLVAFPVAVAAEDEAFLPEPLAPRAPRRPRSPPSSPVFFASPSPTFRRR
LRLLRSCQDLGRQAWAGAGFEAENGPTPSPGRSPLDSQASPGLVLHAGAPPASAGSPSCT AQTATMTCHPRPCPGTHRSPAR |
||||
| Drugs and Mode of Action | |||||
| Drug(s) | NM-702 | Drug Info | Phase 3 | Angina pectoris | [1] |
| Inhibitor | NM-702 | Drug Info | [2] | ||
| References | |||||
| REF 1 | Application of adaptive design and decision making to a phase II trial of a phosphodiesterase inhibitor for the treatment of intermittent claudication. Trials. 2011; 12: 134. | ||||
| REF 2 | The novel phosphodiesterase inhibitor NM-702 improves claudication-limited exercise performance in patients with peripheral arterial disease. J Am Coll Cardiol. 2006 Dec 19;48(12):2539-45. Epub 2006Nov 28. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.